A pharmacist group’s application for Opdivo to be included in the reimbursement list in Turkey has been refused, while a gang stealing other cancer drugs from hospitals has been caught by police. AIDS cases are on the increase and new standards for stem cell treatments will be enforced through a certification program.
A PharmAsia News update on Turkish biomedical regulatory policies. For the previous article in the series, see ([A#28150603001]).
The Healthcare Services Pricing Commission of SGK (the Social Security Institution of Turkey, the national medicines payor) has refused to add Bristol-Myers Squibb Co.’s cancer drug Opdivo (nivolumab) 10...
Pharma firms tended to downplay first-quarter trends in full-year guidance. However, raised guidance seems fragile amid ongoing foreign exchange effects and Medicare Part D redesign pressures.
The Trump administration released more details on “most favored nation” price targets drug companies are expected to apply to US drug prices.
Lupin CEO Vinita Gupta speaks on Trump’s most favored nation policy, the Inflation Reduction Act’s “pill penalty” and other developments in the US, a major market for the company. The company also outlines a five-year plan focused on complex generics and technology platforms.
Policy experts and pharma executives react to President Trump’s executive order on “equalizing” drug prices between the US and comparable nations at the ISPOR 2025 conference.
Small-cell lung cancer treatment is rapidly evolving, but Jazz and Roche are set to create a new maintenance therapy setting with their Zepzelca plus Tecentriq combination.
All eyes are on the upcoming readout of BPL-003 for treatment-resistant depression.
The information flow in the months before the approval of GSK’s Nucala in COPD provides an interesting case study, and brings to mind the cautionary tale of Alnylam’s Onpattro.
